Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranexa MERLIN study complete

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CV Therapeutics expects top-line data from its MERLIN study of Ranexa (ranolazine) in the first quarter of 2007. The firm announced Sept. 26 that MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is complete and will soon move to the close-out phase. MERLIN was designed under a special protocol assessment with FDA; the agreement stipulates that if the primary endpoint of time to first occurrence of any element of a composite endpoint is met, Ranexa could potentially be approved for treatment of ACS and secondary prevention. CVT has also said it believes MERLIN would support a labeling expansion to first-line angina (1Pharmaceutical Approvals Monthly May 2005, p. 10)...

You may also be interested in...



Ranexa Angina Reduction Enough For Restricted Indication, CVT Says

A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease

Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply

ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.

China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC

The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel